Fig. 7

EGFR amplification in IDH-wildtype glioblastoma: a, comparison of our dataset with a previously published dataset [39] shows that the ratio of EGFR amplified and non-amplified, TERT-mutant GBM is similar to the published cohort (p = 0.3). Instead, the ratio of EGFR amplified and non-amplified, TERT-wildtype GBM is different between both cohorts (p = 0.04). b, comparison of the prevalence of EGFR status in GBM in our cohort (London, RT-PCR quantification) with those from the published dataset (“HD”, determined with the copy number readout from the methylation arrays) [39], shows no statistically significant difference (χ² 2.3, p = 0.13). c, comparison of EGFR status in our cohort determined with Illumina arrays and with RT-PCR. There is a 95% concordance between both methods (χ² 0.21, p = 0.64). EGFR was determined as amplified by RT-PCR where 6 and more copies were calculated with the CopyCaller™ software. EGFR data extracted from the copy number variation plot (downloadable from www.molecularneuropathology.org) were called amplified if the intensity was higher than 0.6 on a log2-scale [39]